Changes of Cardiopulmonary Function After Thrombolysis in Patients With Pulmonary Embolism

Launched by BIN HE · Feb 14, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how the heart and lungs function in patients who have a condition called acute pulmonary embolism (PE) after they receive a treatment called thrombolysis. Thrombolysis is a procedure that helps dissolve blood clots that block blood flow. The researchers want to see how different measures of heart and lung function change after this treatment to find the best ways to tell if the treatment is working quickly.

To participate in the trial, you need to be between 65 and 74 years old, or between 29 and 219 years old, and have been diagnosed with medium-high risk or high-risk pulmonary embolism that is treated with thrombolysis. Unfortunately, if there’s no imaging evidence of PE, if you pass away within 48 hours after the treatment, or if you are pregnant, you would not be eligible to participate. If you join the trial, you'll be monitored to see how your heart and lungs respond after the thrombolysis, helping doctors understand how to improve treatment for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • medium-high risk or high risk pulmonary embolism and treated with thrombolysis
• Exclusion Criteria:
• • lack of radiologic evidence to diagnose APE
• • death within 48 hours after thrombolytic therapy
• • unable to partner treatment and leaving hospitals
• • missing other necessary data
• • pregnancy